Phoenix Clinical Research Center   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Beirut Lebanon (2012)

Organization Overview

First Clinical Trial
2012
NCT01511731
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Phoenix Clinical Research

Active Ingredients

Drugs in Phase 3 Trials (1)

fibrinogen (human) (RiaSTAP) (1 trial)

Drugs in Phase 2 Trials (2)

compound 121564 (1 trial)

compound 2055269 (1 trial)

Drugs in Phase 1 Trials (2)

famotidine (pepcid) (1 trial)

trl1068 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Afibrinogenemia (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 5